RHYTHM PHARMACEUTICALS, INC.RYTMEarnings & Financial Report
Nasdaq
RYTM Q3 2025 Key Financial Metrics
Revenue
$51.3M
Gross Profit
$45.8M
Operating Profit
$-52.7M
Net Profit
$-52.9M
Gross Margin
89.3%
Operating Margin
-102.6%
Net Margin
-103.1%
YoY Growth
54.3%
EPS
$-0.82
Financial Flow
RHYTHM PHARMACEUTICALS, INC. Q3 2025 Financial Summary
RHYTHM PHARMACEUTICALS, INC. reported revenue of $51.3M for Q3 2025, with a net profit of $-52.9M (-103.1% margin). Cost of goods sold was $5.5M, operating expenses totaled $98.5M.
Key Financial Metrics
| Total Revenue | $51.3M |
|---|---|
| Net Profit | $-52.9M |
| Gross Margin | 89.3% |
| Operating Margin | -102.6% |
| Report Period | Q3 2025 |
RHYTHM PHARMACEUTICALS, INC. Annual Revenue by Year
RHYTHM PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $130.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $130.1M |
| 2023 | $77.4M |
| 2022 | $23.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.2M | $26.0M | $29.1M | $33.3M | $41.8M | $32.7M | $48.5M | $51.3M |
| YoY Growth | 175.7% | 126.4% | 51.3% | 47.8% | 72.6% | 25.9% | 66.8% | 54.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $332.7M | $258.7M | $381.8M | $363.6M | $392.3M | $386.7M | $372.7M | $506.9M |
| Liabilities | $163.0M | $197.1M | $202.4M | $210.9M | $227.7M | $223.6M | $239.2M | $211.2M |
| Equity | $169.8M | $61.6M | $39.3M | $11.2M | $21.7M | $18.9M | $-11.9M | $148.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.4M | $-40.7M | $-29.1M | $-25.2M | $-18.8M | $-40.4M | $-23.3M | $-26.6M |